Study of a new drug for advanced stomach cancer after prior treatments
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have advanced stomach or gastroesophageal junction cancer that has worsened after at least two prior treatments.
- A tumor sample shows your cancer has the CLDN18.2 protein at a certain level (tested by a central lab).
- You have at least one measurable tumor (largest tumor ≤5 cm) or an evaluable lesion.
- You are in generally good health (ECOG score 0 or 1) and expected to live at least 12 weeks.
- Your heart, liver, kidney, and blood counts meet safety thresholds.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (CT041) given after surgery and chemotherapy to prevent stomach cancer from coming back. It is for people whose tumors have a specific protein (CLDN18.2) and who have already had standard treatment.
This study tests a combination of three treatments—JS107, toripalimab (an immunotherapy), and chemotherapy—for advanced stomach cancer that has a specific protein marker called CLDN18.2. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial collects tissue samples to study why some stomach cancers become resistant to treatment. It aims to better understand how tumors and their surroundings interact, which could help doctors choose the right therapy for each patient.
This trial tests a new cell therapy (CT041) for people with advanced stomach or gastroesophageal junction cancer that has a specific marker called CLDN18.2. It is given after initial chemotherapy to try to keep the cancer from growing.
This trial tests a new therapy called CT0494BCP for advanced stomach cancer (including cancers at the junction between the esophagus and stomach) that hasn't responded to at least two prior treatments. The therapy is designed to target a specific protein called CLDN18.2 found on your cancer cells, combined with immune-boosting treatment.
This trial tests a three-drug combination (anlotinib, TQB2450, and nab-paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has progressed after prior treatment with a CLDN18.2-targeted regimen. The goal is to see if this new combination can shrink tumors and help patients live longer.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.